Dalzanemdor and its Impurities

Dalzanemdor, previously known as SAGE-718, is an investigational drug developed by Sage Therapeutics. It is an oral positive allosteric modulator of the N-methyl-D-aspartate receptor. Reference standards of Dalzanemdor API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.